Search
Facial Skin Wrinkles
go.drugbank.com/conditions/DBCOND0057699Drugs: Botulinum toxin type ASynonyms: Lined faceElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.
Ulceration of the mouth
go.drugbank.com/conditions/DBCOND0100372Drugs: Apremilast · Benzethonium · Benzocaine · Choline salicylate · Dequalinium · Lidocaine +7 moreSynonyms: Pain in oral cavitySimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.
Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, ARZOMEBA PISA 500MG/500MG (IMIPENEM+CILASTATINA) POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLESynonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalWhile AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … US in December 2021.
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … in 2014.
Categories: Drugs Used in DiabetesPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast … [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.
Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnIt is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis. … Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis.
Mixtures: STRODAY D3 2G/800 IU SAŞE , 28 SAŞE, FULLBONE D3 2 G/800 IU EFERVESAN TABLET, 30 ADET